We are live on
!
Find out more
TA
TLS Advisors Portfolio holdings
AUM
$34M
1-Year Est. Return
11.11%
This Fund
S&P 500
This Quarter
Est. Return
-3.77%
1 Year Est. Return
+11.11%
3 Year Est. Return
+36.15%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$40M
AUM Growth
-$3M
(-7%)
Cap. Flow
+$2.47M
Cap. Flow
% of AUM
6.18%
Top 10 Holdings %
Top 10 Hldgs %
93.23%
Holding
19
New
4
Increased
2
Reduced
1
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nucor
NUE
|
+$1.39M |
| 2 |
BHP
BHP
|
+$697K |
| 3 |
Weyerhaeuser
WY
|
+$464K |
| 4 |
Vale
VALE
|
+$433K |
| 5 |
ENZ
Enzo Biochem, Inc.
ENZ
|
+$15.3K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ovid Therapeutics
OVID
|
+$541K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 49.19% |
| 2 | Energy | 17.98% |
| 3 | Healthcare | 15.59% |
| 4 | Communication Services | 14.1% |
| 5 | Consumer Discretionary | 1.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
BHP
BHP
$245B
| $7.08M | 17.71% |
123,960
+12,000
| +11% | +$697K |
|
2
Rio Tinto
RIO
$170B
| $6.8M | 17.01% |
103,100
| – | – |
|
3
EQT Corp
EQT
$34.3B
| $5.58M | 13.96% |
150,800
| – | – |
|
4
Meta Platforms (Facebook)
META
$1.45T
| $5.34M | 13.36% |
10,589
| – | – |
|
|
5
Vale
VALE
$65.2B
| $4.51M | 11.3% |
404,000
+36,000
| +10% | +$433K |
|
|
XOMA
6
DELISTED
Xoma
XOMA
| $2.85M | 7.14% |
120,365
| – | – |
|
7
Range Resources
RRC
$9.73B
| $1.61M | 4.02% |
47,923
| – | – |
|
8
Xenon Pharmaceuticals
XENE
$6B
| $1.28M | 3.22% |
32,956
| – | – |
|
|
9
Nucor
NUE
$57.3B
| $1.26M | 3.16% |
+8,000
| New | +$1.39M |
|
10
OmniAb
OABI
$670M
| $938K | 2.35% |
250,185
| – | – |
|
|
11
Ovid Therapeutics
OVID
$572M
| $866K | 2.17% |
1,125,296
-194,383
| -15% | -$541K |
|
12
Hovnanian Enterprises
HOV
$743M
| $549K | 1.37% |
3,872
| – | – |
|
|
13
Weyerhaeuser
WY
$17.1B
| $426K | 1.07% |
+15,000
| New | +$464K |
|
|
NBIS
14
Nebius Group N.V.
NBIS
$59.4B
| $294K | 0.74% |
17,811
| – | – |
|
15
Regeneron Pharmaceuticals
REGN
$83.2B
| $263K | 0.66% |
250
| – | – |
|
16
iShares MSCI Singapore ETF
EWS
$1.23B
| $261K | 0.65% |
13,600
| – | – |
|
17
Alset
AEI
$57.2M
| $18K | 0.05% |
+11,140
| New | +$8.88K |
|
|
ENZ
18
DELISTED
Enzo Biochem, Inc.
ENZ
| $14K | 0.04% |
+13,616
| New | +$15.3K |
|
19
Retractable Technologies
RVP
$21.6M
| $13K | 0.03% |
12,152
| – | – |
|
Similar funds
QC
CPCM
EGI
SL
LWM
RF
MUMSS
CGIM
TLS Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, TLS Advisors held 19 positions worth $40M, down 7% from $43M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
TLS Advisors deployed $2.47M of net new capital in Q2 2024, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Nucor: 8,000 shares worth $1.26M.
By sector, the portfolio is most concentrated in Materials at 49% of assets, up from 41% a quarter earlier, followed by Energy and Healthcare.
On the sell side, the largest reduction was Ovid Therapeutics, an estimated $541K trimmed.
- TLS Advisors's largest Q2 2024 buy was Nucor: 8,000 shares worth $1.26M.
- TLS Advisors added most to BHP in Q2 2024, an estimated $697K increase.
- TLS Advisors's biggest Q2 2024 reduction was Ovid Therapeutics, cutting an estimated $541K.
- TLS Advisors's ten largest holdings make up 93% of its $40M portfolio in Q2 2024.
- TLS Advisors opened 4 new positions and closed 0 in Q2 2024.
- TLS Advisors's portfolio value fell 7% quarter-over-quarter to $40M.
Based on TLS Advisors's 13F filing for Q2 2024, filed 7 Aug 2024.